BIO 5192

Drug Profile

BIO 5192

Alternative Names: BIO5192

Latest Information Update: 22 Feb 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biogen Idec
  • Class Anti-inflammatories; Butyric acids; Pyrrolidines; Small molecules
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 09 Jan 2004 A preclinical study has been added to the Neurological disorders pharmacodynamics section
  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
  • 28 Oct 2003 Preclinical trials in Multiple sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top